Literature DB >> 26377476

Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.

Jonathan M Ehrich1, Daniel I Messinger2, Cerise R Knakal3, Jamie R Kuhar2, Selena S Schattauer2, Michael R Bruchas2, Larry S Zweifel4, Brigitte L Kieffer5, Paul E M Phillips4, Charles Chavkin6.   

Abstract

The endogenous dynorphin-κ opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls the risk of depression-like and addiction behaviors; however, the molecular and neural circuit mechanisms are not understood. In this study, we report that KOR activation of p38α MAPK in ventral tegmental (VTA) dopaminergic neurons was required for conditioned place aversion (CPA) in mice. Conditional genetic deletion of floxed KOR or floxed p38α MAPK by Cre recombinase expression in dopaminergic neurons blocked place aversion to the KOR agonist U50,488. Selective viral rescue by wild-type KOR expression in dopaminergic neurons of KOR(-/-) mice restored U50,488-CPA, whereas expression of a mutated form of KOR that could not initiate p38α MAPK activation did not. Surprisingly, while p38α MAPK inactivation blocked U50,488-CPA, p38α MAPK was not required for KOR inhibition of evoked dopamine release measured by fast scan cyclic voltammetry in the nucleus accumbens. In contrast, KOR activation acutely inhibited VTA dopaminergic neuron firing, and repeated exposure attenuated the opioid response. This adaptation to repeated exposure was blocked by conditional deletion of p38α MAPK, which also blocked KOR-induced tyrosine phosphorylation of the inwardly rectifying potassium channel (GIRK) subunit Kir3.1 in VTA dopaminergic neurons. Consistent with the reduced response, GIRK phosphorylation at this amino terminal tyrosine residue (Y12) enhances channel deactivation. Thus, contrary to prevailing expectations, these results suggest that κ opioid-induced aversion requires regulation of VTA dopaminergic neuron somatic excitability through a p38α MAPK effect on GIRK deactivation kinetics rather than by presynaptically inhibiting dopamine release. SIGNIFICANCE STATEMENT: Kappa opioid receptor (KOR) agonists have the potential to be effective, nonaddictive analgesics, but their therapeutic utility is greatly limited by adverse effects on mood. Understanding how KOR activation produces dysphoria is key to the development of better analgesics and to defining how the endogenous dynorphin opioids produce their depression-like effects. Results in this study show that the aversive effects of κ receptor activation required arrestin-dependent p38α MAPK activation in dopamine neurons but did not require inhibition of dopamine release in the nucleus accumbens. Thus, contrary to the prevailing view, inhibition of mesolimbic dopamine release does not mediate the aversive effects of KOR activation and functionally selective κ opioids that do not activate arrestin signaling may be effective analgesics lacking dysphoric effects.
Copyright © 2015 the authors 0270-6474/15/3512917-15$15.00/0.

Entities:  

Keywords:  GIRK; depression; dopamine; dynorphin; kappa opioid receptor; stress

Mesh:

Substances:

Year:  2015        PMID: 26377476      PMCID: PMC4571610          DOI: 10.1523/JNEUROSCI.2444-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Causal relationship between stressful life events and the onset of major depression.

Authors:  K S Kendler; L M Karkowski; C A Prescott
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  The therapeutic potential of κ-opioids for treatment of pain and addiction.

Authors:  Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2011-01       Impact factor: 7.853

Review 4.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

5.  Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.

Authors:  T S Shippenberg; R Bals-Kubik; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

6.  Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine.

Authors:  Stephanie L Borgland; Sharif A Taha; Federica Sarti; Howard L Fields; Antonello Bonci
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

7.  Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens.

Authors:  Jonathan M Ehrich; Paul E M Phillips; Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2014-06-27       Impact factor: 7.853

8.  Repeated stress dysregulates κ-opioid receptor signaling in the dorsal raphe through a p38α MAPK-dependent mechanism.

Authors:  Julia C Lemos; Clarisse A Roth; Daniel I Messinger; Harminder K Gill; Paul E M Phillips; Charles Chavkin
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

9.  Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety.

Authors:  Larry S Zweifel; Jonathan P Fadok; Emmanuela Argilli; Michael G Garelick; Graham L Jones; Tavis M K Dickerson; James M Allen; Sheri J Y Mizumori; Antonello Bonci; Richard D Palmiter
Journal:  Nat Neurosci       Date:  2011-04-17       Impact factor: 24.884

Review 10.  The kappa opioid receptor: from addiction to depression, and back.

Authors:  Laurence Lalanne; Gulebru Ayranci; Brigitte L Kieffer; Pierre-Eric Lutz
Journal:  Front Psychiatry       Date:  2014-12-08       Impact factor: 4.157

View more
  68 in total

Review 1.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

2.  Structural Remodeling of Sympathetic Innervation in Atherosclerotic Blood Vessels: Role of Atherosclerotic Disease Progression and Chronic Social Stress.

Authors:  Crystal M Noller; Armando J Mendez; Angela Szeto; Marcia Boulina; Maria M Llabre; Julia Zaias; Neil Schneiderman; Philip M McCabe
Journal:  Psychosom Med       Date:  2017-01       Impact factor: 4.312

3.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

4.  Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry.

Authors:  Alexander F Hoffman; Charles E Spivak; Carl R Lupica
Journal:  ACS Chem Neurosci       Date:  2016-03-28       Impact factor: 4.418

Review 5.  Endogenous opioid peptides in the descending pain modulatory circuit.

Authors:  Elena E Bagley; Susan L Ingram
Journal:  Neuropharmacology       Date:  2020-05-15       Impact factor: 5.250

Review 6.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

7.  Kappa counterconditioning of cocaine cues.

Authors:  John R Mantsch; Robert C Twining
Journal:  Neuropsychopharmacology       Date:  2018-03-06       Impact factor: 7.853

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Authors:  Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.